Arcutis Publications

Sort by:

Disease State

Conference

Sort by:

Medical Conferences

Academy of Managed Care Pharmacy 2022 Annual Meeting

Effects of Roflumilast Cream on Patient Burden and Work Productivity in Patients With Psoriasis

PDF Icon.

American Academy of Dermatology 2022

Pooled Efficacy and Safety Results From the DERMIS-1 and DERMIS-2 Phase 3 Trials of Once-Daily Roflumilast Cream 0.3% by Baseline Body Surface Area

PDF Icon.

Pooled Efficacy and Safety Results From the DERMIS-1 and DERMIS-2 Phase 3 Trials of Once-Daily Roflumilast Cream 0.3% for Treatment of Chronic Plaque Psoriasis

PDF Icon.

Efficacy and Safety of Once-Daily Roflumilast Cream 0.3% in Patients With Knee/Elbow Involvement: Pooled Results From Phase 3 Trials (DERMIS-1 and DERMIS-2)

PDF Icon.

Long-term Safety and Efficacy of Roflumilast Cream 0.3% in Patients With Chronic Plaque Psoriasis: Interim Results From a 24-Week, Phase 3 Open-Label Study

PDF Icon.

Effect of Roflumilast Foam 0.3% Treatment of Seborrheic Dermatitis on Patient Quality of Life: Results From a Phase 2 Study

PDF Icon.

European Academy of Dermatology and Venereology 2021

Roflumilast Cream 0.3% For the Severity and Impact of Itch in Patients With Chronic Plaque Psoriasis in the Phase 3 DERMIS-1 and DERMIS-2 Studies

PDF Icon.

Once-Daily Roflumilast Foam 0.3% For Severity and Burden of Itch in Patients With Scalp and Body Psoriasis in a Randomized, Double-blind, Vehicle-Controlled Phase 2b Study

PDF Icon.

Safety and Efficacy of Once-Daily Roflumilast Cream 0.3%, a Potent Phosphodiesterase-4 Inhibitor for the Treatment of Psoriasis in the DERMIS-1 and DERMIS-2 Phase 3 Trials

PDF Icon.

A Randomized, Double-blind, Vehicle-Controlled Phase 2a Study Evaluating Once Daily Roflumilast Foam 0.3% in Patients With Moderate to Severe Seborrheic Dermatitis

PDF Icon.

European Academy of Dermatology and Venereology Spring Symposium 2021

Roflumilast Cream, a Once-Daily, Potent Phosphodiesterase-4 Inhibitor, in Chronic Plaque Psoriasis Patients: Efficacy and Safety From DERMIS-1 and DERMIS-2 Phase 3 Trials

PDF Icon.

American Academy of Dermatology 2021

The PASI-HD For Precision in Measuring Disease Severity in Subjects With Mild to Moderate Plaque Psoriasis Treated With Roflumilast Cream, a Phosphodiesterase-4 Inhibitor

PDF Icon.

Correlation of Itch Response to Roflumilast Cream With Disease Severity and Patient-Reported Outcomes in Patients With Chronic Plaque Psoriasis

PDF Icon.

Effect of Roflumilast Cream on Chronic Plaque Psoriasis in Patients With Steroid-Sensitive Area Involvement

PDF Icon.

Efficacy and Safety of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis in a Randomized, Double-Blind, Vehicle-Controlled Phase 2 Study

PDF Icon.

Once-Daily Roflumilast Foam 0.3% for Scalp and Body Psoriasis: A Randomized, Double-Blind, Vehicle-Controlled Phase 2b Study

PDF Icon.

Innovations in Dermatology 2021

Long-term Safety and Efficacy of Roflumilast Cream 0.3% in Adult Patients With Chronic Plaque Psoriasis: Results From a 52-Week, Phase 2b Open-Label Study

PDF Icon.

American Academy of Dermatology 2020

ARQ-151, Roflumilast Cream, For Psoriasis in Phase 2a Study

PDF Icon.

ARQ-151, Roflumilast Cream, For Chronic Plaque Psoriasis in Phase 2b Study

PDF Icon.

European Academy of Dermatology and Venereology 2020

The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Atopic Dermatitis: Phase 2 Proof-of-Concept Study

PDF Icon.

Roflumilast Cream (ARQ-151) 0.15% and 0.3% For Symptom Burden in Adults With Chronic Plaque Psoriasis in a Phase 2b Study

PDF Icon.

Roflumilast Cream (ARQ-151) For Itch Severity and Itch-Related Sleep Loss in Adults With Chronic Plaque Psoriasis in a Phase 2b Study

PDF Icon.
null

The information contained in this website is intended for healthcare professionals (HCPs) only.



You are now leaving the Arcutis medical affairs website. Arcutis Biotherapeutics is not responsible for the content of linked sites.



Doximity social icon.
Doximity social icon.